Can Dual Long-Acting Bronchodilator Therapy Prevent Clinically Important Deteriorations In Chronic Obstructive Pulmonary Disease? A Post Hoc Analysis Of The Zep117115 Trial

被引:0
|
作者
Singh, D. [1 ]
Maleki-Yazdi, M. [2 ]
Tombs, L. [3 ]
Naya, I. [3 ]
Church, A. [4 ]
Iqbal, A. [4 ]
机构
[1] Univ Manchester, Med Evaluat Unit, Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England
[2] Univ Toronto, Womens Coll Hosp, Div Resp Med, Toronto, ON, Canada
[3] GlaxoSmithKline, Stockley Pk, England
[4] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A5760
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting 2-Agonist Therapy: An Integrated Post Hoc Analysis
    Naya, Ian P.
    Tombs, Lee
    Lipson, David A.
    Compton, Chris
    ADVANCES IN THERAPY, 2018, 35 (10) : 1626 - 1638
  • [32] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
    Ian P. Naya
    Lee Tombs
    David A. Lipson
    Chris Compton
    Advances in Therapy, 2018, 35 : 1626 - 1638
  • [33] Late Breaking Abstract - Evening Administration of Long-Acting Muscarinic Antagonists in Chronic Obstructive Pulmonary Disease to Prevent Exacerbations
    Sivapalan, Pradeesh
    Romer, Valdemar
    Jordan, Alexander
    Johansen, Niklas Dyrby
    Pareek, Manan
    Modin, Daniel
    Mathioudakis, Alexander
    Vestbo, Jorgen
    Eklof, Josefin
    Hurst, John R.
    Klausen, Tobias Wirenfeldt
    Biering-Sorensen, Tor
    Jensen, Jens-Ulrik Staehr
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [34] Forced Oscillation Technique Measurements Relate To Hyperinflation And Lung Volume Improvements Following Long-Acting Bronchodilator In Chronic Obstructive Pulmonary Disease
    Milne, S.
    Hammans, C.
    Watson, S.
    Farah, C. S.
    Thamrin, C.
    King, G. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [35] A Composite Endpoint of Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease and Its Association with Increased Mortality: A Post Hoc Analysis of the UPLIFT Study
    Han, M. K.
    Halpin, D. M.
    Martinez, F. J.
    Miravitlles, M.
    Singh, D.
    de la Hoz, A.
    Voss, F.
    Rabe, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [36] A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
    Masato Muraki
    Yuki Kunita
    Ken Shirahase
    Ryo Yamazaki
    Soichiro Hanada
    Hirochiyo Sawaguchi
    Yuji Tohda
    BMC Pulmonary Medicine, 21
  • [37] A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
    Muraki, Masato
    Kunita, Yuki
    Shirahase, Ken
    Yamazaki, Ryo
    Hanada, Soichiro
    Sawaguchi, Hirochiyo
    Tohda, Yuji
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [38] LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A RARE EVENTS META ANALYSIS OF CLINICALLY RELEVANT ADVERSE EVENTS
    Dranitsaris, G.
    Schmitz, S.
    Adunlin, G.
    Lindner, L.
    Rea, R.
    VALUE IN HEALTH, 2014, 17 (03) : A172 - A172
  • [39] Long-acting muscarinic antagonist and long-acting beta 2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery
    Makino, Takashi
    Otsuka, Hajime
    Hata, Yoshinobu
    Koezuka, Satoshi
    Azuma, Yoko
    Isobe, Kazutoshi
    Sugino, Keishi
    Ebihara, Sitorlt
    Homma, Sakae
    Iyoda, Akira
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 647 - 652
  • [40] Use of long-acting triple therapy for chronic obstructive pulmonary disease (COPD) in practice: The ELETHON physicians' survey
    Beeh, Kai-Michael
    Kruege, Saskia
    PNEUMOLOGIE, 2024,